Search
Fate Therapeutics Inc
FATEAdd to Watchlist
1.280USD
-0.060-4.48%
Close 11-13 16:00（ET）
153.37MMarket Cap
LossP/E TTM
Fate Therapeutics Inc (FATE) Stock Price Target & Forecast
Analyst Rating
Based on 12 analysts giving stock ratings to Fate Therapeutics Inc in the past month.
Buy
3 Strong Buy
3 Buy
6 Hold
0 Sell
0 Strong Sell
Target Price
5.243USD+152.06%
FATE Analyst Recommendation Trends
In the current month, FATE has received 3 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. FATE average Analyst price target in the last month is 5.243.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
6
6
6
6
6
6
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
12
12
12
12
12
12
FATE Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Apple Inc
AAPL
9
16
14
3
1
43
Ge Vernova Inc
GEV
10
21
6
1
0
38
Tapestry Inc
TPR
5
12
4
1
0
22
Verisk Analytics Inc
VRSK
5
6
9
0
0
20
FMC Corp
FMC
1
4
12
2
0
19
Avantor Inc
AVTR
1
1
15
1
0
18
Elanco Animal Health Inc
ELAN
5
9
2
0
0
16
Genuine Parts Co
GPC
2
3
8
0
0
13
Canadian Solar Inc
CSIQ
1
3
6
3
0
13
Willscot Holdings Corp
WSC
4
0
7
0
0
11
Financial Forecasting
Based on analysts' estimates, FATE EPS is projected to reach -0.249 in FY2026Q4, following reported EPS of -0.248 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.28
-0.27
-0.27
-0.25
-0.26
Actual
-0.26
-0.25
-0.25
--
--
Surprise
+7.13%
+6.47%
+8.13%
--
--
FAQs
What is Fate Therapeutics Inc's expected revenue for the next quarter?
Fate Therapeutics Inc's expected revenue is 833.33K.
What is Fate Therapeutics Inc's price target?
Analysts forecast that Fate Therapeutics Inc's price target is USD 5.24, with the highest forecast at USD 8.00 and the lowest forecast at USD 2.20.
How have Fate Therapeutics IncFATE's recent earnings per share performed?
The market expectation was USD -0.25, while Fate Therapeutics IncFATE's earnings per share (EPS) for the previous quarter was USD -0.25. EPS for the next quarter is expected at USD -0.25.
What is the analyst rating for Fate Therapeutics Inc?
Based on the ratings of Fate Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.